158 related articles for article (PubMed ID: 21481618)
1. A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer.
Cetnar J; Wilding G; McNeel D; LoConte NK; McFarland TA; Eickhoff J; Liu G
Urol Oncol; 2013 May; 31(4):436-41. PubMed ID: 21481618
[TBL] [Abstract][Full Text] [Related]
2. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
Sternberg CN; Petrylak DP; Sartor O; Witjes JA; Demkow T; Ferrero JM; Eymard JC; Falcon S; Calabrò F; James N; Bodrogi I; Harper P; Wirth M; Berry W; Petrone ME; McKearn TJ; Noursalehi M; George M; Rozencweig M
J Clin Oncol; 2009 Nov; 27(32):5431-8. PubMed ID: 19805692
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
Mardjuadi F; Medioni J; Kerger J; D'Hondt L; Canon JL; Duck L; Musuamba F; Oudard S; Clausse M; Moxhon A; Machiels JP
Cancer Chemother Pharmacol; 2012 Aug; 70(2):293-303. PubMed ID: 22752248
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
Masters GA; Brockstein BE; Mani S; Ratain MJ
Med Oncol; 2003; 20(1):7-12. PubMed ID: 12665678
[TBL] [Abstract][Full Text] [Related]
5. A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.
Chu FM; Picus J; Fracasso PM; Dreicer R; Lang Z; Foster B
Invest New Drugs; 2011 Aug; 29(4):674-9. PubMed ID: 20145975
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
Rosenberg JE; Ryan CJ; Weinberg VK; Smith DC; Hussain M; Beer TM; Ryan CW; Mathew P; Pagliaro LC; Harzstark AL; Sharib J; Small EJ
J Clin Oncol; 2009 Jun; 27(17):2772-8. PubMed ID: 19349545
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
Morris MJ; Pandit-Taskar N; Carrasquillo J; Divgi CR; Slovin S; Kelly WK; Rathkopf D; Gignac GA; Solit D; Schwartz L; Stephenson RD; Hong C; Delacruz A; Curley T; Heller G; Jia X; O'Donoghue J; Larson S; Scher HI
J Clin Oncol; 2009 May; 27(15):2436-42. PubMed ID: 19364960
[TBL] [Abstract][Full Text] [Related]
8. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Creel P; Turnbull J; Moore C; Jaffe TA; Haley S; Petros W; Yenser S; Gockerman JP; Sleep D; Hurwitz H; George DJ
Clin Cancer Res; 2008 Oct; 14(19):6270-6. PubMed ID: 18829508
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
Zurita AJ; George DJ; Shore ND; Liu G; Wilding G; Hutson TE; Kozloff M; Mathew P; Harmon CS; Wang SL; Chen I; Chow Maneval E; Logothetis CJ
Ann Oncol; 2012 Mar; 23(3):688-694. PubMed ID: 21821830
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer.
Vaishampayan UN; Fontana J; Heilbrun LK; Smith D; Heath E; Dickow B; Figg WD
Urol Oncol; 2014 Jan; 32(1):31.e25-33. PubMed ID: 23433892
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.
Garcia JA; Hutson TE; Shepard D; Elson P; Dreicer R
Cancer; 2011 Feb; 117(4):752-7. PubMed ID: 20922803
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of docetaxel plus ifosfamide in patients with advanced cancer.
Marx G; Lewis C; Hall K; Levi J; Ackland S
Br J Cancer; 2002 Oct; 87(8):846-9. PubMed ID: 12373597
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer.
Sternberg CN; Whelan P; Hetherington J; Paluchowska B; Slee PH; Vekemans K; Van Erps P; Theodore C; Koriakine O; Oliver T; Lebwohl D; Debois M; Zurlo A; Collette L;
Oncology; 2005; 68(1):2-9. PubMed ID: 15741753
[TBL] [Abstract][Full Text] [Related]
14. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
15. Satraplatin: BMS 182751, BMY 45594, JM 216.
Drugs R D; 2007; 8(2):125-32. PubMed ID: 17324011
[TBL] [Abstract][Full Text] [Related]
16. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.
Gelmon KA; Stewart D; Chi KN; Chia S; Cripps C; Huan S; Janke S; Ayers D; Fry D; Shabbits JA; Walsh W; McIntosh L; Seymour LK
Ann Oncol; 2004 Jul; 15(7):1115-22. PubMed ID: 15205207
[TBL] [Abstract][Full Text] [Related]
18. Commentary on "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial." Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Medical Oncology and Biostatistics, Institut Paoli-Calmettes, Marseille, France. Lancet Oncol 2013;14(2):149-58 [Epub 2013 Jan 8].
Trump DL
Urol Oncol; 2013 Nov; 31(8):1845. PubMed ID: 24210084
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.
Schneider BJ; Kalemkerian GP; Bradley D; Smith DC; Egorin MJ; Daignault S; Dunn R; Hussain M
Invest New Drugs; 2012 Feb; 30(1):249-57. PubMed ID: 20686817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
